Summary of COVID-19 iC1e/K studies

1. Mansour et al., Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19

20 patient iC1e/K late treatment RCT: no change in mortality (p=1) and 35% lower hospital discharge (p=0.36).
RCT 30 severe COVID-19 patients showing no significant difference in mortality or hospitalization time with kinin-kallikrein system inhibitors icatibant or iC1e/K. While there was no impact on mortality or hospitalization time, both treatments were safe and showed improvements in lung CT scores and increased blood eosinophil counts.
Feb 2021, Viruses, https://www.mdpi.com/1999-4915/13/2/309, https://c19p.org/mansour3